Pancreatic ductal adenocarcinoma (PDAC), a rare but lethal tumor, is difficult to diagnose without performing an invasive procedure. miRNAs are known to be deregulated in PDAC patients, and recent studies have shown that they can be used as diagnostic and prognostic of the disease. The detection of miRNAs in samples acquired through minimally or noninvasive procedures, such as serum, plasma, and saliva, can have a positive impact on the clinical management of these patients. This article is a comprehensive review of the major studies that have evaluated the expression of miRNAs as biomarkers in pancreatic cancer and its premalignant lesions
Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy with a high rate of mortality an...
A severe lack of early diagnosis coupled with resistance to most available therapeutic options rende...
A severe lack of early diagnosis coupled with resistance to most available therapeutic options rende...
Le Ren, Yue Yu Department of Gastroenterology, Affiliated Provincial Hospital, Anhui Medical Univer...
Pancreatic ductal adenocarcinoma (PDAC) is a tumor with a poor prognosis, short overall survival and...
Pancreatic ductal adenocarcinoma (PDAC) is a tumor with a poor prognosis, short overall survival and...
Pancreatic ductal adenocarcinoma (PDAC) is a tumor with a poor prognosis, short overall survival and...
Pancreatic ductal adenocarcinoma (PDAC) is a tumor with a poor prognosis, short overall survival and...
Pancreatic ductal adenocarcinoma (PDAC) is a tumor with a poor prognosis, short overall survival and...
Ductal adenocarcinoma (PDAC) is the most common primary pancreatic neoplasm. It's frequently diagnos...
Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy with increasing incidence and hi...
Pancreatic ductal adenocarcinoma (PDAC) is increasing in incidence and is still associated with a hi...
Background: Pancreatic ductal adenocarcinoma (PDAC) is the most common type of PCa with 2-9% 5-year ...
Abstract Despite tremendous research efforts focused on diagnosis and treatment, pancreatic ductal a...
Due to its aggressive and late presentation, there is an urgent need for novel and reliable biomarke...
Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy with a high rate of mortality an...
A severe lack of early diagnosis coupled with resistance to most available therapeutic options rende...
A severe lack of early diagnosis coupled with resistance to most available therapeutic options rende...
Le Ren, Yue Yu Department of Gastroenterology, Affiliated Provincial Hospital, Anhui Medical Univer...
Pancreatic ductal adenocarcinoma (PDAC) is a tumor with a poor prognosis, short overall survival and...
Pancreatic ductal adenocarcinoma (PDAC) is a tumor with a poor prognosis, short overall survival and...
Pancreatic ductal adenocarcinoma (PDAC) is a tumor with a poor prognosis, short overall survival and...
Pancreatic ductal adenocarcinoma (PDAC) is a tumor with a poor prognosis, short overall survival and...
Pancreatic ductal adenocarcinoma (PDAC) is a tumor with a poor prognosis, short overall survival and...
Ductal adenocarcinoma (PDAC) is the most common primary pancreatic neoplasm. It's frequently diagnos...
Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy with increasing incidence and hi...
Pancreatic ductal adenocarcinoma (PDAC) is increasing in incidence and is still associated with a hi...
Background: Pancreatic ductal adenocarcinoma (PDAC) is the most common type of PCa with 2-9% 5-year ...
Abstract Despite tremendous research efforts focused on diagnosis and treatment, pancreatic ductal a...
Due to its aggressive and late presentation, there is an urgent need for novel and reliable biomarke...
Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy with a high rate of mortality an...
A severe lack of early diagnosis coupled with resistance to most available therapeutic options rende...
A severe lack of early diagnosis coupled with resistance to most available therapeutic options rende...